Natera, Inc. $NTRA Stock Position Decreased by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS reduced its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 28.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,387 shares of the medical research company’s stock after selling 7,250 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Natera were worth $7,600,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in NTRA. BlackRock Inc. purchased a new position in Natera in the 2nd quarter valued at approximately $2,962,770,000. Arrowstreet Capital Limited Partnership grew its stake in shares of Natera by 1.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after acquiring an additional 11,793 shares in the last quarter. Maverick Capital Ltd. grew its stake in shares of Natera by 24.1% in the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after acquiring an additional 227,605 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Natera by 10.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after acquiring an additional 80,440 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of Natera during the second quarter worth $199,960,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider John Fesko sold 6,517 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the transaction, the insider owned 197,257 shares in the company, valued at approximately $63,424,043.21. The trade was a 3.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 1,906 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $425.55, for a total value of $811,098.30. Following the completion of the transaction, the chief financial officer directly owned 46,574 shares in the company, valued at $19,819,565.70. This trade represents a 3.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 53,573 shares of company stock worth $19,856,400. 5.05% of the stock is currently owned by company insiders.

Analyst Ratings Changes

NTRA has been the topic of several analyst reports. TD Cowen increased their price objective on Natera from $340.00 to $480.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Citigroup lifted their target price on Natera from $365.00 to $480.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. Robert W. Baird set a $348.00 target price on Natera in a research note on Friday, August 7th. Barclays upped their price target on Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $363.50 price target on shares of Natera in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $391.69.

Natera Stock Down 14.6%

Shares of Natera stock opened at $310.67 on Friday. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41. The company has a market capitalization of $44.78 billion, a P/E ratio of -272.52 and a beta of 1.55. The company has a 50 day moving average of $380.25 and a 200 day moving average of $269.68.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative net margin of 5.66% and a negative return on equity of 8.73%. The firm had revenue of $793.98 million during the quarter, compared to analysts’ expectations of $707.54 million. During the same period in the prior year, the company posted ($0.64) earnings per share. The company’s revenue for the quarter was up 34.1% on a year-over-year basis. As a group, research analysts anticipate that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
• Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
• Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Natera Profile

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection.